Our Recommendations
New Publications
- Chagas Clinical Research Platform (2022)
- Comparison of the Influence of Different Nucleic Acid Extraction Assays on the Sensitivity of Trypanosoma cruzi-Specific Real-Time PCR (2022)
- Diagnosis and Prevalence of Chagas Disease in an Indigenous Population of Colombia (2022)
- Diagnosis and Clinical Management of Chagas Disease (2022)
- Prevalence of Common Diseases in Indigenous People in Colombia (2022)
Filter
36
Featured
Recommendations
1
Language
Document type
Studies & Reports
29
Resource Platforms
5
Strategic & Response Plan
1
No document type
1
Countries / Regions
Global
7
Colombia
5
Paraguay
2
Mexico
1
El Salvador
1
Latin America and the Carribbean
1
Authors & Publishers
Publication Years
Category
Studies & Reports
5
Chagas
2
Toolboxes
Chagas disease or American trypanosomiasis is, together with geohelminths, the neglected disease that causes more loss of years of healthy life due to disability in Latin America. Chagas disease, as determined by the factors and determinants, shows that different contexts require different actions, ...
[Presentación] El presente libro, elaborado por integrantes de múltiples generaciones
de técnicos e investigadores salvadoreños dedicados a la enfermedad de Chagas, refleja claramente su actual situación epidemiológica, la evolución
histórica de la misma y los retos y perspectivas que la...
[Antecedentes] En el año 2005, un brote registrado en un área turística del sur de Brasil, concitó la atención internacional en función de haber afectado a un grupo de turistas internacionales y haber registrado alta morbilidad y mortalidad. La importancia que reviste este tema emergente, y la...
Congenital transmission of Chagas disease has not been extensively studied in Colombia, and there are no standardized processes in the health system regarding
the specific diagnosis, treatment and follow-up of this disease. To generate recommendations on congenital Chagas disease and Chagas in wom...
La enfermedad de Chagas, también llamada tripanosomiasis americana, sigue siendo endémica en 21 países de América Latina. Sin embargo, como consecuencia de las migraciones, la urbanización, la intensificación del turismo, la modificación de las estrategias agrícolas y el cambio climático, l...
It is 101 years since Carlos Chagas discovered the parasite responsible for the disease that now bears his name. What progress has been made since this discovery? Here Julie Clayton gives the low-down on Chagas disease.
Chagas disease is currently endemic and also predicted to be at increased transmission risk under future climate change scenarios. Similarly, an expansion of areas in the United States at increased risk for Chagas disease transmission is also expected over the next several decades under climate chan...
The Indigenous tribe called the Wiwa lives retracted in the Sierra Nevada de Santa Marta, Colombia. Little is known about their health status and whether the health care system in place covers their needs.
Chagas Disease (CD) affects 6–7 million people worldwide and isrelated topoverty-promo ting conditions. Chronic asymptomatic cases are mostly invisible tohealth systems. Aiming totranslate CD discoveries into education/information practices toraise alertness and empowerment ofaffected people; and ...
Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga...
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address
the many outstanding rese...
This report provides a review and analysis of the research landscape for three diseases – Chagas disease, human African trypanosomiasis and leishmaniasis – that disproportionately afflict poor and remote populations with limited access to health services. It represents the work of the disease re...
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...
Chagas disease affects 8-10 million people worldwide, mainly in Latin America. The current therapy for Chagas disease is limited to nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease but with severe side effects. Therefore, there is an unmet need for new...
Paraguay muestra avances en el compromiso asumido, de avanzar hacia la Salud Uni¬versal. La experiencia ha demostrado que el proceso puede acelerarse cuando existe un fuerte involucramiento social. En este marco se realizó un llamado a los líderes del MSPYBS, la sociedad civil y público en gener...
El proyecto “Abordar las Enfermedades Infecciosas Desatendidas (EID) y las arbovirosis en el Chaco Paraguayo” ejecutado en el period 2017-2018 en el Chaco paraguayo por el Ministerio de Salud Pública y Bienestar Social de Paraguay (MSPyBS) con la cooperación técnica de la Representación en e...
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease
(CD). T. cruzi is transmitted by triatomine insects, congenitally, through uncontrolled blood donations and organ transplants,
and via consumption of food or drink contaminated by triatomi...
For the molecular diagnosis of Chagas disease by real-time PCR (polymerase chain reaction), optimization of diagnostic accuracy is desirable. The detection limit of real-time PCR assays for the diagnosis of Trypanosoma cruzi in human serum is affected by various influences including the choice of th...
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps...
